Beyond Air, Inc. (XAIR) |
|
5.77 -0.17 (-2.86%)
|
11-28 16:00 |
|
Open: |
5.93 |
Pre. Close: |
5.94 |
|
High:
|
5.95 |
Low:
|
5.62 |
|
Volume:
|
204,671 |
Market Cap:
|
173(M) |
|
|
|
Technical analysis |
as of: 2022-11-28 4:44:23 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 7.83 One year: 8.95 |
| Support: |
Support1: 5.15 Support2: 4.29 |
| Resistance: |
Resistance1: 6.71 Resistance2: 7.67 |
| Pivot: |
6 |
| Moving Average: |
MA(5): 5.95 MA(20): 6.18
MA(100): 8.26 MA(250): 7.6 |
| MACD: |
MACD(12,26): -0.4  Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 39.1 %D(3): 41.1 |
| RSI: |
RSI(14): 41.1 |
| 52-week: |
High: 13.05 Low: 4.78 |
| Average Vol(K): |
3-Month: 184 (K) 10-Days: 199 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ XAIR ] has closed above bottom band by 30.6%. Bollinger Bands are 52.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
5.96 - 6 |
6 - 6.03 |
|
Low:
|
5.51 - 5.57 |
5.57 - 5.61 |
|
Close:
|
5.69 - 5.77 |
5.77 - 5.83 |
|
Company Description |
|
Beyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. |
Headline News |
Mon, 28 Nov 2022
Kickin’ Facts with Legendary Lade | DJ Khaled We The Best x Air Jordan 5 “Sail” - REVOLT
Thu, 24 Nov 2022
Beyond Air: Opportunistic Entry With LungFit PRO Updates (XAIR) - Seeking Alpha
Wed, 23 Nov 2022
Will Beyond Air (NASDAQ:XAIR) Spend Its Cash Wisely? - Yahoo Lifestyle UK
Tue, 22 Nov 2022
Tuesday 11/22 Insider Buying Report: XAIR, LPLA - Nasdaq
Sun, 20 Nov 2022
Beyond Air, Inc.'s (NASDAQ:XAIR) Director Purchases 10000 Shares of Stock - Best Stocks
Wed, 16 Nov 2022
The A Ma Maniére x Air Jordan 4 “Violet Ore” Releases Globally On November 23rd - Sneaker News
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Medical Devices |
| Shares Out. |
30 (M) |
| Shares Float |
25 (M) |
|
% Held by Insiders
|
15.7 (%) |
|
% Held by Institutions
|
19.1 (%) |
|
Shares Short
|
1,220 (K) |
|
Shares Short P.Month
|
1,080 (K) |
Stock Financials |
|
EPS
|
-1.22 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
1.97 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
-38.1 |
|
Return on Equity (ttm)
|
-101.6 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
-1.37 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-30 (M) |
|
Levered Free Cash Flow
|
-18 (M) |
Stock Valuations |
|
PE Ratio
|
-4.77 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
2.92 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
-5.7 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
2017-01-09 |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
